First presentation of clinical data from ET programme demonstrating a consistent and clinically meaningful platelet control with favourable tolerability profile; VECTRA trial will ...

Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore ...

Enrollment began in the U.S. in June 2022 and expanded to China, New Zealand, Australia, and India. The topline results summary reports 659 patients: 164 assigned to CBT-001 0.1%, 329 to CBT-001 0.2%, ...

In China, New Drug Applications (“NDAs”) for sovleplenib in primary ITP and warm AIHA (“wAIHA”) are currently under regulatory review by the National Medical Products Administration (NMPA), supported ...

Total revenue for the third quarter was $302.3 million, an increase of $73.2 million or 32.0% over the prior year quarter; Net income for the third quarter was $9.6 million, an increase of $3.6 ...

Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will ...

GAAP net loss per share for the third quarter of 2026 was $0.12 compared to $0.13 for the third quarter of 2025. Non-GAAP net loss per share for the third quarter of 2026 was $0.11 compared to $0.12 ...

Net Product Revenue: RASONQUE net product revenue was $197.6 million for the quarter ended September 30, 2026, reflecting approximately five weeks of commercial availability following U.S. FDA ...

Following the conclusion of the fireside chat, a replay will be available for 30 days on the “ Events and Presentations ” page of Larimar’s website.

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance ...

Third Quarter 2026 Financial Results Revenue for the third quarter of 2026 was $24.9 million, an increase of 25% compared to the same period in the prior year. IG revenue was $21.0 million, an ...

Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the ...